HealthEquity, Inc.

Fundamentals7.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • High margins
  • Strong FCF
  • Intangible concentration

AI
AI Summary

6.0

HealthEquity has shifted from an account‑growth story to a cash‑and‑margin story where upside now hinges on custodial yield normalization driving sustainable margin expansion and FCF conversion rather than multiple expansion from account growth. Investors should watch custodial yields, margin cadence, and management's capital allocation (buybacks/M&A) as the key catalysts/risks, with margin rollback or sizable intangible impairments likely to trigger quick multiple compression — downside if price falls below the 75.6–75.9 support cluster.

CashYield
ImpairmentRisk
Valuation‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • High margins
  • Strong FCF
  • Intangible concentration

HQY delivers strong liquidity, high margins and robust free cash flow but trades at a premium with sizeable intangible-assets risk that could amplify downside.

StrongLiquidity
IntangibleRisk

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Above last month SMA
  • Neutral momentum
  • Range-bound action

HQY is trading above its last month SMA (~$78.50) within a contained $75.60–$81.15 range, with a neutral RSI (~48) implying modest upside potential but limited momentum and risk of a drop if support fails.

contained
tailrisk
Support Level: $75.60–$75.90
Resistance Level: $81.15

Earlier large drawdowns this year increase tail-risk if support breaks

Sentiment & News

7.0

Key News Insights:

  • Record revenue/profits
  • Custodial yield tailwind
  • Mixed analyst reactions

HealthEquity beat Q4 estimates with record revenue and a 123% jump in net income—driven by higher custodial yields and HSA growth—prompting higher FY27 outlooks amid mixed analyst responses and active institutional rebalancing.

Outperformance
InstitutionalFlows

Clearer earnings visibility and margin expansion should support the stock, though upside may be tempered by analyst caution and portfolio rebalances